Morgan Stanley analyst Jeffrey Hung raised his price target on Voyager Therapeutics (VYGR) shares to $28 from $21 after the company recently announced that it will be getting back rights to VY-HTT01 for Huntington's disease in a restructuring of its partnership with Sanofi Genzyme (SNY). While early in development, Hungs think VY-HTT01 could be a roughly $900M product for Voyager. Although he appreciates the opportunity in Huntington's and is "constructive" on VY-AADC in Parkinson's, Hung keeps an Equal Weight rating on Voyager shares, citing what he sees as limited near-term clinical catalysts.

Reports business EPS of EUR 1.78, down 17.6% reported and 7.4% at CER. Reports Q1 IRFS net sales EUR 10.464B, up 2.4%. Paul Hudson, Chief Executive Officer, commented: "We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. Continued strong performance by Dupixent and our new launches drove sales growth of seven percent. In parallel, we are delivering on our promise of increased investments in our late-stage pipeline to fully realize its value for patients and Sanofi. We are awaiting regulatory decisions for Dupixent in COPD, a progressive disease with limited effective treatment options. If approved, Dupixent will be the first biologic treatment in COPD. With the robust progress in our portfolio transformation, we reaffirm our financial guidance for 2024."